Induced pluripotent stem cells as a model for diabetes investigation

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Stepniewski, J ^a   Kachamakova Trojanowska, N ^a   Ogrocki, D ^a   Szopa, M ^b,c   Matlok, M ^b   Beilharz, M ^a   Dyduch, G ^a   Malecki, M T ^b,c   Jozkowicz, A ^a   Dulak, J ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD15 ANTIGEN; HOMEODOMAIN PROTEIN; NANOG PROTEIN, MOUSE; NUCLEAR PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, MOUSE;

ADULT; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; EMBRYOID BODY; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PLURIPOTENT STEM CELL;

ADULT; ANIMALS; ANTIGENS, CD15; BIOMARKERS; CELL DIFFERENTIATION; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; EMBRYOID BODIES; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MICE, INBRED C57BL; MICE, OBESE; MIDDLE AGED; NUCLEAR PROTEINS; OCTAMER TRANSCRIPTION FACTOR-3;

EID: 84923899767     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08597     Document Type: Article

References (52)

1. Danaei, G. et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31-40 (2011).
2. Petersen, K. F. & Shulman, G. I. Etiology of insulin resistance. Am J Med 119(Suppl 1), 10-16 (2006).
3. Kahn, C. R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43, 1066-1084 (1994).
4. Roberts, A. C. & Porter, K. E. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res 10, 472-482 (2013).
5. Chen, H. et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84, 491-495 (1996).
6. King, A. J. The use of animal models in diabetes research. Br J Pharmacol 166, 877-894 (2012).
7. Yoshida, S. et al. AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun 400, 745-751 (2010).
8. Gault, V. A., Kerr, B. D., Harriott, P. & Flatt, P. R. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin Sci (Lond) 121, 107-117 (2011).
9. Kavvoura, F. K. & Owen, K. R. Maturity onset diabetes of the young: clinical characteristics, diagnosis and management. Pediatr Endocrinol Rev 10, 234-242 (2012).
10. Yamagata, K. et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384, 455-458 (1996).
11. Malecki, M. T. & Mlynarski, W. Monogenic diabetes: implications for therapy of rare types of disease. Diabetes Obes Metab 10, 607-616 (2008).
12. Yang, Q. et al. Hepatocyte nuclear factor-1alpha modulates pancreatic beta-cell growth by regulating the expression of insulin-like growth factor-1 in INS-1 cells. Diabetes 516, 1785-1792 (2002).
13. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
14. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
15. Jang, J. et al.Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery. Exp Mol Med 44, 202-213 (2012).
16. Kudva, Y. C. et al. Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Transl Med 1, 451-461 (2012).
17. Teo, A. K. et al. Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. J Biol Chem 288, 5353-5356 (2013).
18. Hua, H. et al. iPSC-derived b cells model diabetes due to glucokinase deficiency. J Clin Invest 123, 3146-3153 (2013).
19. Liu, J. et al. Generation of stable pluripotent stem cells from NOD mouse tail-tip fibroblasts. Diabetes 60, 1393-1398 (2011).
20. Liu, Y. J. et al. Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages. Blood 103, 4449-4456 (2004).
21. Zambidis, E. T. et al. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 112, 3601-3614 (2008).
22. Grochot-Przeczek, A. et al.Heme oxygenase-1 is required for angiogenic function of bone marrow-derived progenitor cells: role in therapeutic revascularization. Antioxid Redox Signal 20, 1677-1692 (2014).
23. Poels, M. W. J. et al. Enhanced Collagen Type IV Based Differentiation of Embryonic Stem Cells Towards Flk-1 Expressing Vascular Progenitors by the Wnt/b-Catenin Synergist QS11. Macromol Symp 309-310, 236-243 (2011).
24. Pagliuca, F. W. et al. Generation of functional human pancreatic b cells in vitro. Cell 159, 428-439 (2014).
25. Jeon, K. et al. Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells Dev 21, 2642-2655 (2012).
26. Ding, H. & Triggle, C. R. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag 1, 55-71 (2005).
27. Hadi, H. A. & Suwaidi, J. A. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 3, 853-876 (2007).
28. Fadini, G. P. et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 45, 1449-1457 (2005).
29. Menegazzo, L., Albiero, M., Avogaro, A. & Fadini, G. P. Endothelial progenitor cells in diabetes mellitus. Biofactors 38, 194-202 (2012).
30. Ren, J. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinol 181, 1-10 (2004).
31. Schroeter, M. R. et al. Leptin promotes the mobilization of vascular progenitor cells and neovascularization by NOX2-mediated activation of MMP9. Cardiovasc Res 93, 170-180 (2012).
32. Basile, D. P. & Yoder, M. C. Circulating and tissue resident endothelial progenitor cells. J Cell Physiol 229, 10-16 (2014).
33. Józkowicz, A. et al. Nitric oxide mediates the mitogenic effects of insulin and vascular endothelial growth factor but not of leptin in endothelial cells. Acta Biochim Pol 46, 703-715 (1999).
34. Park, H. Y. et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33, 95-102 (2001).
35. Nakagawa, K. Leptin causes vasodilation in humans. Hypertens Res 25, 161-165 (2002).
36. Matsuda, K. et al. Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 26, 147-152 (2003).
37. Fagiani, E. & Christofori, G. Angiopoietins in angiogenesis. Cancer Lett 328, 18-26 (2013).
38. Józkowicz, A. et al. Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid Redox Signal 5, 155-162 (2003).
39. Dulak, J., Deshane, J., Jozkowicz, A. & Agarwal, A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 117, 231-241 (2008).
40. Schiekofer, S., Galasso, G., Sato, K., Kraus, B. J. & Walsh, K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 25, 1603-1609 (2005).
41. Kotlinowski, J. et al. PPARc activation but not PPARc haplodeficiency affects proangiogenic potential of endothelial cells and bone marrow-derived progenitors. Cardiovasc Diabetol 13, 150 (2014).
42. Chan, E. M., Ratanasirintrawoot, S. & Park, I. H. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol 27, 1033-1037 (2009).
43. Hrvatin, S. et al. Differentiated human stem cells resemble fetal, not adult, b cells. Proc Natl Acad Sci USA 111, 3038-3043 (2014).
44. Machalinska, A. et al. Long-term neuroprotective effects of NT-4-engineered mesenchymal stem cells injected intravitreally in a mouse model of acute retinal injury. Invest Ophthalmol Vis Sci 54, 8292-8305 (2013).
45. Sommer, C. A. et al. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27, 543-549 (2009).
46. Watanabe, K. et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 25, 681-686 (2007).
47. Castegnaro, M., Massey, R. C. & Walters, C. L. The collaborative evaluation of a procedure for the determination of N-nitroso compounds as a group. Food Addit Contam 4, 37-43 (1987).
48. Maehr, R. et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci USA 106, 15768-15773 (2009).
49. Schroeder, I. S., Rolletschek, A., Blyszczuk, P., Kania, G. & Wobus, A. M. Differentiation of mouse embryonic stem cells to insulin-producing cells. Nat Protoc 1, 495-507 (2006).
50. Suzuki, J. et al. Antizyme is necessary for conversion of pancreatic tumor cells into glucagon-producing differentiated cells. Endocr Relat Cancer 16, 649-59 (2009).
51. Sommer, C. A. et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 28, 64-74 (2010).
52. Kang, N. Y., Yun, S. W., Ha, H. H., Park, S. J. & Chang, Y. T. Embryonic and induced pluripotent stem cell staining and sorting with the live-cell fluorescence imaging probe CDy1. Nat Protoc 6, 1044-1052 (2011).